Moderate to severe neurodevelopmental outcome at 18 to 24 months№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Moderate or severe OHSS · assisted reproduction technology cycles
1 finding from 1 review
Moderate or severe OHSS ‐ Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol · assisted reproduction technology cycles
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Moderate or severe OHSS ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Moderate or severe OHSS · assisted reproduction technology cycles
It is very uncertain whether summary of findings table ‐ Progestagen changes moderate or severe OHSS compared with gnRH agonist (very low certainty).
1 finding from 1 review
Moderate or severe OHSS · assisted reproduction technology cycles
1 finding from 1 review
5a. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5a.Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Moderate‐dose atropine (0.1% to < 0.5%) · children with progressive myopia (26 studies, 4949 participants in the analysis) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
Moderate‐dose atropine (0.1% to < 0.5%) · children with progressive myopia (38 studies, 6525 participants in analyses) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
Moderate‐dose atropine (0.1% to < 0.5%) · children with progressive myopia (36 studies, 6263 participants) in the analysis Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
Moderate‐dose atropine (0.1% to < 0.5%) · children with progressive myopia (21 studies, 4169 participants in the analysis) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Moderate‐severe nasal injury · preterm infants receiving nasal CPAP
Bubble probably leads to higher moderate‐severe nasal injury compared with ventilator or Infant Flow Driver nasal continuous positive airway… (moderate certainty).
1 finding from 1 review
Intervention not reported
Anthropometric recovery: percentage of children who recover from moderate or severe wasting Defined as % children aged 6–59 months who recovered in treatment programmes for moderate or severe malnutrition (Wroe 2021) · children aged > 6 months and ≤ 5 years with wasting
1 finding from 1 review
Intervention not reported
Appropriate referral of children with moderate or severe wasting · children aged > 6 months and ≤ 5 years with wasting
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Appropriate referral of children with moderate or severe wasting · children aged > 6 months and < 5 years with wasting
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found